The US Senate passed a reworked Biosecure Act as an amendment to the National Defense Authorization Act, seeking to restrict certain federal contracting and funding relationships with companies deemed 'of concern'—a move aimed at reducing perceived national security risks in biotechnology collaborations. The amendment removed specific company names from earlier drafts while maintaining restrictive language. Lead sentence: The Senate-approved NDAA amendment revives the Biosecure Act with broader, less targeted language that could constrain federal engagements with some foreign-linked biotech firms. The change reflects ongoing legislative scrutiny around supply‑chain security and foreign influence in critical bio‑infrastructure. Industry groups and researchers previously warned the bill could hamper scientific collaboration and access to instrumentation or reagents; the bill now moves into bicameral reconciliation, where differences with the House version will determine its final scope. Companies and research institutions should track implementation language and potential exceptions for research and clinical needs.